Anti-Serum Amyloid P Antibody, Non-Fucosylated (BioBet-571ZP) (CAT#: BioBet-571ZP) Datasheet

APCS

amyloid P component, serum

The protein encoded by this gene is a glycoprotein, belonging to the pentraxin family of proteins, which has a characteristic pentameric organization. These family members have considerable sequence homology which is thought to be the result of gene duplication. The binding of the encoded protein to proteins in the pathological amyloid cross-beta fold suggests its possible role as a chaperone. This protein is also thought to control the degradation of chromatin. It has been demonstrated that this protein binds to apoptotic cells at an early stage, which raises the possibility that it is involved in dealing with apoptotic cells in vivo.

APCS; amyloid P component, serum; SAP; PTX2; HEL-S-92n; serum amyloid P-component; pentaxin-related; 9.5S alpha-1-glycoprotein; epididymis secretory sperm binding protein Li 92n

Extracellular region or secreted

Diseases associated with PITX2 include Ring Dermoid Of Cornea and Anterior Segment Dysgenesis 4.

Its related pathways are Regulation of Wnt-mediated beta catenin signaling and target gene transcription and Heart Development.

Control cell proliferation in a tissue-specific manner and participate in morphogenesis. It plays a role in the expansion of muscle progenitor cells during embryonic development. May play a role in the correct positioning of asymmetric organs such as the heart and stomach. The PTX2C subtype is involved in left-right asymmetry (through similarity) in the developing embryo.

Cell Biology and Cellular Response antibody; Neuroscience antibody

N-glycosylated with a complex biantennary oligosaccharide chain with a sialic acid at the end (disialo-SAP). Monosialo-SAP as well as asioalo-SAP are also detected

Protein Based Therapies
Monoclonal antibody (mAb)

lgG2a

BioBet-571ZP

Mouse

Human

Anti-SAP antibody treatment is clinically feasible because circulating human SAP can be depleted in patients by the bis-D-proline compound, CPHPC4, thereby enabling injected anti-SAP antibody to reach residual SAP in the amyloid deposits. The unprecedented capacity of this novel combined therapy to eliminate amyloid deposits should be applicable to all forms of systemic and local amyloidosis.

Systemic amyloidosis

Systemic amyloidosis